Pharmacy

ERT, a global technology-driven provider of clinical services and   customisable   medial devices to biopharmaceutical and healthcare organizations, recently   announced   that its Board of Directors has appointed Dr Jeffrey S Litwin as its new President & Chief  Executive Officer (CEO) and a member of the board.

Dr Joel Morganroth, who had served as interim President and CEO, commented, "After a thorough national search by Heidrick and Struggles, our Board selected Dr Litwin, an internal candidate, as the most qualified person to lead ERT. Dr Litwin brings to ERT knowledge of the clinical research domain, that is our core business, and also experience in the adjacent markets of phase IV safety surveillance and healthcare in which ERT's assets will be employed. All of our employees look forward to continuing to work with Jeff to enhance ERT's operational successes and strategy."

Dr Litwin joined ERT in 2000 as Senior Vice President and Chief Medical Officer and was subsequently promoted in December 2005 to Executive Vice President and Chief Medical Officer. Dr Litwin oversaw ERT's global cardiac safety

operations for seven years and was instrumental in implementing EXPERT, ERT's digital operating system. During this time period, ERT experienced tremendous growth with revenues increasing more than three-fold. For the last four years, he has been responsible for leading ERT's consulting business, assisting over 150 companies with the design and evaluation of cardiac safety testing programmes.